BIVI stock icon



About: BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 18

Funds holding %
of 6,689 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

53% more capital invested

Capital invested by funds: $2.32M [Q4 2023] → $3.55M (+$1.23M) [Q1 2024]

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

7.34% more ownership

Funds ownership: 4.87% [Q4 2023] → 12.21% (+7.34%) [Q1 2024]

7% less funds holding

Funds holding: 54 [Q4 2023] → 50 (-4) [Q1 2024]

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

85% less call options, than puts

Call options by funds: $27.3K | Put options by funds: $187K

Research analyst outlook

We haven’t received any recent analyst ratings for BIVI.

Financial journalist opinion